<--- Back to Details
First PageDocument Content
Medical terms / Gynaecological cancer / Anatomical pathology / Breast disease / Dysplasia / Pap test / Breast cancer / Fibrocystic breast changes / Bethesda System / Medicine / Papillomavirus / Oncology
Date: 2008-03-27 16:38:53
Medical terms
Gynaecological cancer
Anatomical pathology
Breast disease
Dysplasia
Pap test
Breast cancer
Fibrocystic breast changes
Bethesda System
Medicine
Papillomavirus
Oncology

Ladies First ICD9CM Codes

Add to Reading List

Source URL: healthvermont.gov

Download Document from Source Website

File Size: 279,10 KB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document